A Study of BG-C477 in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT06596473
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 310
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BG-C477 (drug), Tislelizumab (drug), Chemotherapy (drug)
- Dates
- Started 2024-10-03; completion 2028-07-23
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $1.3M in research payments for this study in 2025 (68 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Marwan G. Fakih, MD Medical Oncology · Duarte, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Weijing Sun, MD Medical Oncology · Westwood, KS
- Siqing Fu, MD, PH D Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Yale University $448,191
- Ut MD Anderson Cancer Center $364,337
- City of Hope National Medical Ctr $297,332
- University of Kansas Medical Center Research Institute, Inc. $202,153
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.